Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2017
NCT03220178
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 5